Quantcast
HEALTH CARE

Medical Devices Drive Health Care M&A

Pacemakers, catheters and other innovative products that lower costs and improve outcomes are in high demand

The health care industry is receiving more than its fair share of attention these days. With the implementation of the Affordable Care Act well under way and the U.S. government supporting an expanded health care system, strategic buyers and private equity firms alike are clamoring to invest in the health care sector. In fact, according to a survey conducted by KPMG LLP, 60 percent of M&A professionals working in the health care sector indicated they would do more deals in 2013 than they did in 2012. The medical device subsector, which includes a broad range of instruments and products used to diagnose, prevent or treat disease, has become a main driver of M&A transactions within the health care space. Deals involving medical devices, such as pacemakers, surgical blades and catheters, had the greatest gains in deal value within the health care industry during 2012. In the fourth quarter alone, 16 medical device M&A deals closed, representing a total value of $3.4 billion, according to PricewaterhouseCoopers.

Medical device companies have become popular with private equity investors and strategic acquirers for a number of reasons. According to ReportLinker, the value of the global medical device industry is expected to reach $228 billion by 2015, up from $164 billion in 2010, marking annual growth of nearly 7 percent. This is no surprise when considering that life expectancy has risen by nearly 20 years over the past 50 years, increasing the need for medical devices. Additionally, worldwide demographics are increasingly shifting toward older populations. Between 2000 and 2050, developed regions will see their over-60 age group grow to 34 percent of the total population, up from less than 20 percent. The aging population, coupled with lifestyle-related diseases, ensures increasing market demand for the medical device industry. Strategic acquirers are making the biggest push in the space, purchasing a wide variety of medical device companies. Flush with cash, it's a smart move for strategic acquirers to buy medical device companies rather than rely on organic growth alone, which can be slow. Strategic buyers need to stay current as the health care industry evolves under the new government initiatives, and they are finding deal flow from the venture community.

This makes sense, considering venture capital is heavily invested in the space. U.S.-based medical device companies raised a total of $2.44 billion from venture capitalists in 2012. Additionally, venture disbursements to U.S. medical device companies climbed by 32 percent in the fourth quarter of 2012, to $581 million from $440 million. This is set against a backdrop of overall venture capital investment (for all sectors) falling by 3 percent in the fourth quarter, according to the PricewaterhouseCooper's quarterly MoneyTree report.

Strategic acquirers such as Abbott Laboratories (NYSE: ABT), Boston Scientific Corp. (NYSE: BSX), Covidien (NYSE: COV), Johnson & Johnson (NYSE: JNJ), Medtronic Inc. (NYSE: MDT), Stryker Corp. (NYSE: SYK) and St. Jude Medical Inc. (NYSE: STJ) have bought or invested in early-stage, venture-backed medical device companies recently.

For example, in 2012 alone, Covidien bought or invested in five venture-backed medical device companies. Its most recent acquisition, in January 2013, was CV Ingenuity, a drug-eluting balloon technology company. CV Ingenuity had raised approximately $35 million from venture capital firms such as BioStar Ventures, Life Sciences Angels, New Enterprise Associates, Synergy Ventures and Western Technology Investment. Covidien, which won Mergers & Acquisitions' M&A Mid-Market Award for Strategic Buyer of the Year, spent $1.14 billion on fast-growing acquisition targets in 2012.

"Our investment in companies with products in the development stage allows us to enter new, fast-growing categories much faster than if we used internal development resources," said Amy Wendell, Covidien's senior vice president of strategy and business development, in a February interview with M&A. The company is also committed to organic growth, doubling its spending on research and development over the last five years, she added.

Johnson & Johnson is also showing a strong appetite for acquiring medical device companies. At that beginning of the year, Johnson & Johnson put out a report touting its medical device and diagnostics unit saying that products in this division accounted for 41 percent of its total sales in 2012. In January 2012, the company invested in venture-backed Clarimedix, a manufacturer of therapeutic medical devices, with Highland Country Venture.


Find out more information about people mentioned in this article from our People Database:

Danielle Fugazy
Amy Wendell